{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Krystal Biotech, Inc. overvalued or undervalued?
As of November 7, 2025, Krystal Biotech, Inc. is fairly valued with a P/E ratio of 27, an EV to EBITDA ratio of 23.83, and a PEG ratio of 0.25, showing strong growth potential, while outperforming peers like Halozyme Therapeutics and Elanco Animal Health, and achieving a year-to-date return of 27.36% compared to the S&P 500's 14.40%.
Is Krystal Biotech, Inc. overvalued or undervalued?
As of November 7, 2025, Krystal Biotech, Inc. is fairly valued with a P/E ratio of 27, a PEG ratio of 0.25 indicating potential undervaluation relative to growth prospects, and has outperformed the S&P 500 with a year-to-date return of 26.34%.
Krystal Biotech Hits New 52-Week High of $212.98, Showcasing Strong Growth
Krystal Biotech, Inc. has achieved a new 52-week high, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector. The company has a market capitalization of USD 4,203 million, a P/E ratio of 27.00, and has reported significant growth in net profit and operating cash flow over recent quarters.
Is Krystal Biotech, Inc. overvalued or undervalued?
As of October 17, 2025, Krystal Biotech, Inc. is considered overvalued with a valuation grade of very expensive, reflected by its high P/E ratio of 27 and strong recent performance, having returned 177.42% over three years compared to the S&P 500's 81.19%.
Krystal Biotech Experiences Revision in Its Stock Evaluation Amid Strong Market Performance
Krystal Biotech, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 27 and a price-to-book value of 4.02. The company demonstrates strong financial metrics, including a ROCE of 36.18% and a year-to-date stock return of 21.43%, outperforming the S&P 500.
Is Krystal Biotech, Inc. overvalued or undervalued?
As of October 17, 2025, Krystal Biotech, Inc. is considered very expensive at $190.23, with elevated valuation ratios compared to peers, despite outperforming the S&P 500 with a 3-year return of 177.42%.
Is Krystal Biotech, Inc. overvalued or undervalued?
As of October 17, 2025, Krystal Biotech, Inc. is considered very expensive with a P/E ratio of 27 and other high valuation metrics, despite strong recent performance and significant returns over five years.
Krystal Biotech Forms Golden Cross, Signaling Potential Bullish Breakout
Krystal Biotech, Inc. has recently achieved a Golden Cross, signaling potential upward momentum. The stock has outperformed the S&P 500 significantly over the past month and year-to-date, with positive technical indicators suggesting strong investor interest as it navigates the Pharmaceuticals & Biotechnology sector.
Krystal Biotech Hits Day High with 9.54% Surge in Strong Performance
Krystal Biotech, Inc. has experienced notable momentum, gaining 9.54% today and outperforming the S&P 500 over various timeframes. The company has shown impressive long-term growth, with a 326.5% increase over the past five and ten years, alongside strong financial metrics and high institutional holdings.
Krystal Biotech Experiences Revision in Stock Evaluation Amid Market Dynamics
Krystal Biotech, Inc. has recently revised its evaluation amid market dynamics, with its stock priced at $167.82. The company has shown significant volatility over the past year, with a 52-week high of $207.84 and a low of $122.80. It has outperformed the S&P 500 in recent months.
Is Krystal Biotech, Inc. technically bullish or bearish?
As of September 26, 2025, Krystal Biotech, Inc. shows a mildly bullish trend with mixed signals across time frames, having outperformed the S&P 500 recently but underperformed over the past year.
Is Krystal Biotech, Inc. technically bullish or bearish?
As of September 26, 2025, Krystal Biotech, Inc. shows a mildly bullish technical trend, with mixed signals across time frames, outperforming the S&P 500 recently but underperforming over the past year.
Is Krystal Biotech, Inc. technically bullish or bearish?
As of September 8, 2025, Krystal Biotech, Inc. shows a mildly bearish trend with mixed technical indicators, having outperformed the S&P 500 in the short term but underperformed over the past year.
Is Krystal Biotech, Inc. overvalued or undervalued?
As of September 11, 2025, Krystal Biotech, Inc. is considered very expensive with high valuation metrics compared to peers, showing a P/E ratio of 27 and underperforming the S&P 500 with a 1-year return of -12.11%.
Krystal Biotech Hits Day High with 8.37% Surge in Stock Price
Krystal Biotech, Inc. has shown notable stock performance, gaining 8.37% on September 15, 2025, and reaching an intraday high of USD 156.25. The company has reported significant net profit growth and has consistently posted positive results for seven quarters, with a market capitalization of USD 4.2 billion.
Is Krystal Biotech, Inc. overvalued or undervalued?
As of May 6, 2025, Krystal Biotech, Inc. is considered overvalued with a P/E ratio of 27 and an EV to EBITDA of 25.02, significantly higher than industry peers, and has underperformed the S&P 500 with a return of -21.11%.
Is Krystal Biotech, Inc. technically bullish or bearish?
As of June 18, 2025, the market trend is mildly bearish, supported by bearish weekly MACD and KST indicators, daily moving averages, and Bollinger Bands, despite a bullish monthly RSI suggesting potential for recovery.
Who are in the management team of Krystal Biotech, Inc.?
As of March 2022, the management team of Krystal Biotech, Inc. includes Chairman and CEO Mr. Krish Krishnan, COO Mrs. Suma Krishnan, Lead Independent Director Mr. R. Douglas Norby, and Directors Dr. Jing Marantz, Dr. Christopher Mason, Mr. Julian Gangolli, and Mr. Kirti Ganorkar. They oversee the company's strategic direction and operations.
What does Krystal Biotech, Inc. do?
Krystal Biotech, Inc. is a gene therapy company focused on developing treatments for dermatological diseases, with a market cap of approximately $3.76 billion. As of March 2025, it reported net sales of $88 million and a net profit of $36 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
